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Background: Glucocorticoids induce hypercholesterolaemia, a cardiovascular risk factor, in patients
with diseases other than rheumatoid arthritis (RA), but the data in RA are contradictory.
Objective: To determine the effects of antirheumatic treatment, including prednisolone (combination)
therapy on total and high density lipoprotein (HDL) cholesterol levels in RA, taking disease activity into
account.
Methods: HDL cholesterol and total cholesterol levels were determined in:(a) established RA (b) two
cohorts with early active RA, (c) a previously conducted 56 week trial among patients with early RA
comparing the value of intensive combination therapy (that included glucocorticoids) with sulfasalazine
alone (COBRA trial).
Results: In established RA total cholesterol levels were only slightly raised, irrespective of disease
activity. However, HDL cholesterol was significantly higher in patients in remission than in patients with
active disease. In contrast, in active early RA at baseline total cholesterol was low normal: between 4.6
and 5.1 mmol/l in the different populations. The level of HDL cholesterol was highly dependent on the
duration of storage. In both COBRA groups total cholesterol increased by a mean of 0.6 mmol/l. HDL
cholesterol increased by more than 50% after treatment, leading to an improvement of the total
cholesterol/HDL ratio (atherogenic index). This increase (and index improvement) was much more
rapid in the group receiving combination treatment. A similar pattern was seen in the 2001 cohort with
early RA. In all the groups with active disease HDL and total cholesterol levels correlated inversely with
disease activity.
Conclusion: In established, but especially in early RA, disease activity is accompanied by atherogenic
lipid levels. This dyslipidaemia can be rapidly reversed by aggressive antirheumatic treatment includ-
ing glucocorticoids.
Mortality is increased in patients with rheumatoidarthritis (RA) compared with the general population,and cardiovascular disease is the most important
cause of death.1 Theoretically, this increased cardiovascular
risk in patients with RA could be caused by (1) an increased
prevalence of (known) risk factors for cardiovascular disease
such as dyslipidaemia, diabetes mellitus, hypertension, body
mass index, physical ﬁtness, and smoking habits; (2) RA itself
by either (a) the underlying inﬂammatory process, or (b)
decreased functional capacity; and (3) undertreatment of
cardiovascular disease as a comorbid condition in patients
with RA (Boers M, unpublished data).
In this investigation we focused on dyslipidaemia. Pub-
lished reports are sparse and contradictory about the levels of
total, high density lipoprotein (HDL) and low density lipopro-
tein cholesterol, and triglycerides in patients with RA, even
though there is some evidence for increased Lp(a) lipoprotein
levels and lowered lipid levels in patients with active disease.1
Glucocorticoids are commonly used in patients with RA.
Although it is well known that glucocorticoids induce hyper-
cholesterolaemia, a well known cardiovascular risk factor, in
patients with diseases other than RA,2 3 the effect of (long
term) glucocorticoid administration on lipid proﬁles in
patients with RA is uncertain. Thus far a limited number of
small scale studies have dealt with this subject in patients
with RA, indicating either an increase or no effect of total
cholesterol levels during (long term) glucocorticoid adminis-
tration.
Therefore, in stored serum samples we investigated total
cholesterol and HDL cholesterol levels cross sectionally, in
patients with early RA4 and in patients with longstanding,
established disease.5 Moreover, we studied the course of lipid
levels and the inﬂuence of antirheumatic treatment (includ-
ing glucocorticoids), in a previously conducted, 56 week
multicentre, randomised controlled trial among patients with
early RA investigating the value of intensive combination
therapy.6 Finally, we determined these levels in one year follow
up samples of the 2001 cohort with early RA.
PATIENTS AND METHODS
This study is the result of an incremental process: the COBRA
trial samples were determined ﬁrst, followed by conﬁrmation
in patients with established active RA and in patients with RA
in remission, and baseline samples of a cohort with early RA
collected in 1996–97. All patients fulﬁlled the American
College of Rheumatology (ACR) 1987 criteria for RA.7 The
apparent effect of serum storage on HDL cholesterol led us to
analyse “fresh” samples of patients with early RA collected in
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2001, and these results prompted us to repeat lipid measure-
ments of these patients after one year, in order to conﬁrm our
ﬁndings in fresh samples.
Cross sectional investigations
Patients with established RA
Serum samples of 56 patients in remission according to the
ACR criteria,8 were matched with serum samples of 56 age and
sex matched patients with established RA with active disease.
The patients had participated in other studies and the samples
were chosen according to availability.5
Most patients were receiving treatment with sulfasalazine
or methotrexate. None of the patients in remission and only a
few patients with active disease used systemic (low dose) glu-
cocorticoids.
Early arthritis clinic 1996–97
Serum samples of a group of 26 patients with early active RA
were used. The samples collected at the ﬁrst visit were selected
according to availability. None of the patients had been treated
with disease modifying antirheumatic drugs (DMARDs) or
glucocorticoids.
Longitudinal investigations
56 Week randomised controlled trial (COBRA)
In this investigation the combination of sulfasalazine, metho-
trexate, and prednisolone (initially 60 mg/day, tapered in six
weekly steps to 7.5 mg/day and stopped after 28 weeks) was
compared with sulfasalazine alone. A total of 155 patients
with early active RA (median disease duration four months)
were randomly assigned to combined treatment (76) or sulfa-
salazine alone (79). Prednisolone and methotrexate were
tapered and stopped after 28 and 40 weeks, respectively. Blood
samples were taken at baseline and at weeks 16, 28, 40, and 56.
Early arthritis clinic 2001
The 2001 group comprised 21 patients with early active RA.
Serum samples collected at the ﬁrst visit were selected
according to availability; none of the patients had been treated
with DMARDs or glucocorticoids. In addition, we determined
lipid levels in one year follow up samples of the group. At this
time most patients had been treated with DMARDs, but only
a few had received glucocorticoids.
Total cholesterol and HDL cholesterol determinations
All (non-fasting) serum samples had been stored at −20°C or
lower. Total serum cholesterol (normal 5.0–6.4 mmol/l) was
measured by an enzymatic method in an autoanalyser; HDL
cholesterol (normal >0.9 mmol/l) was determined enzymati-
cally with polyethylene glycol modiﬁed enzymes.
Although, the classical (chemical) reference value considers
a total cholesterol value of 6.4 mmol/l as the upper limit of
normal we have, for the interpretation of our results, chosen
5.0 mmol/l as the upper limit in view of the recommendations
made by several national and international consensus
committees.9–11 These guidelines were made in view of the
increasing evidence that “high-normal” total cholesterol
serum levels already imply an increased cardiovascular risk.
Likewise an HDL cholesterol level of 1.0 mmol/l instead of 0.9
mmol/l was chosen as the lower limit of normal.
Statistical analyses
All results are expressed as mean (SD). Total cholesterol and
HDL cholesterol and their SD values are expressed in mmol/l.
In patients with established RA a paired t test was used to
analyse the differences between active disease and remission.
Likewise, a paired t test was used to analyse the change
between baseline and one year follow up in the 2001 group
with early RA. Analysis of variance was used to tested the dif-
ferences between the groups with active early and established
RA.
In the COBRA trial, paired and unpaired t tests were used to
analyse the changes within and between the treatment
groups, respectively. Stepwise multiple regression was used to
analyse the changes in lipids up to week 16, with treatment
group, age, sex, disease activity score (DAS) at baseline, eryth-
rocyte sedimentation rate (ESR) at baseline, and changes in
ESR at week 16 as possible predictors. This 16 week period was
chosen for our main analyses as changes in disease activity
and doses of glucocorticoids were most prominent over this
period. Simple regression analysis was used to test the relation
between baseline lipid levels and storage duration.
RESULTS
Patients with established RA
The mean age of the patients with established active disease
was 60 years, and their disease duration was 8 years (table 1).
For patients in remission the mean age was 59 years and the
disease duration 10 years. These patients with established dis-
ease had slightly raised levels of total cholesterol—that is, 5.5
(1.1) and 5.7 (0.8) mmol/l, respectively (table 2). However,
HDL cholesterol levels were signiﬁcantly lower in the patients
with active disease than in those in remission, 0.94 (0.31) v
Table 1 Baseline characteristics of study patients
COBRA
Early arthritis
clinic 1996–97
Early arthritis
clinic 2001
Established
disease active
Established
disease remission
Number 134 26 21 56 56
Age, mean (SD) 50 (12) 62 (17) 60 (14) 60 (13) 59 (14)
No (%) male 55 (41) 9 (35) 8 (38) 9 (16) 9 (16)
Disease duration Median 4 months
(range 1.5–24)
0 months 0 months 8 (9) years 10 (9) years
ESR 55 (33) 52 (28) 43 (30) 39 (22) 15 (15)
DAS28* 5.9 (1.0) 5.2 (0.8) 5.8 (1.0) 5.2 (1.5) <2.6 (0.7)
Disease activity score (28 joints), at baseline >5.1 is high and <2.6 is remission.
Table 2 Total cholesterol, HDL cholesterol and atherogenic index (cholesterol/HDL cholesterol) levels at baseline
COBRA
Early arthritis
clinic 1996–97
Early arthritis
clinic 2001
Established
disease active
Established
disease remission
Total cholesterol (TC) (mmol/l, SD) 4.7 (1.1) 5.1 (1.0) 5.1 (1.0) 5.5 (1.1) 5.7 (0.8)
HDL cholesterol (mmol/l, SD) 0.28 (0.11) 0.49 (0.l3) 1.0 (0.33) 0.94 (0.31) 1.18 (0.13)
TC/HDL cholesterol ratio 16.7 10.4 5.4 6.4 5.1
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1.18 (0.13) (p<0.001), respectively. In explanatory regression
analysis, within the patients with active disease total
cholesterol and HDL cholesterol levels correlated inversely
with disease activity, as assessed by the disease activity index
28 joint score (DAS28).12
Early arthritis clinic 1996–97
The mean age of the patients was 62 years (table 1). At base-
line, total cholesterol was 5.1 (1.0) and HDL cholesterol 0.49
(0.13) in the 1996–97 group.
56 Week randomised controlled trial (COBRA)
The mean age of the patients was 50 years; median disease
duration was four months (table 1). Disease activity improved
more rapidly and effectively in the group receiving combina-
tion therapy at week 16, and this effect persisted until week
28. The clinical difference between the groups decreased and
was no longer signiﬁcant after prednisolone was stopped, and
there were no further changes after methotrexate was
stopped.6 However, persistently lower yearly rates of radiologi-
cal damage progression were observed at least four years after
the trial ended in the (initial) combination group.13
During the trial both groups showed a strong increase from
low baseline cholesterol levels (ﬁg 1), initially more pro-
nounced in the combination group (week 16: 1.1 v 0.6;
p=0.04). Likewise, for HDL cholesterol, both groups showed a
strong increase from a very low baseline level (ﬁg 1). At week
16 the increase in HDL cholesterol was much more
pronounced in the combination group ( 0.18 v 0.05; p<0.001);
this difference was still apparent at week 28 (0.16 v 0.10;
p=0.02). Likewise, at week 16 the decrease in atherogenic
index was more rapid in the combination group (–5.1 v –1.4;
p=0.008). Thereafter, it decreased gradually in the sulfa-
salazine group, but remained stable in the combination group,
resulting in similar values at week 28 and thereafter (ﬁg 1). Of
note, the changes in lipids were mirrored by the pattern of
weight gain, initially greater in the combination group, but
more than 3 kg in both groups at 56 weeks (data not shown).
Regression analysis on the changes at week 16 showed that
changes in total cholesterol were only predicted by changes in
ESR. The change in HDL cholesterol levels at week 16 could be
partially predicted by the change in ESR and DAS at baseline.
However, the treatment group was a more important predictor
independently of the ESR or DAS. Similar ﬁndings were found
for the ratio total cholesterol/HDL cholesterol
Early arthritis clinic 2001
The mean age of the patients was 60 years (table 1) and at
baseline the total cholesterol was 5.1 (1.0) mmol/l and HDL
cholesterol 1.0 (0.33) mmol/l (table 2). After one year the total
cholesterol had increased to 5.8 (1.4) (p< 0.005 compared
with baseline) and HDL to 1.23 (0.39) (p<0.005). The athero-
genic index—that is, total cholesterol/HDL cholesterol ratio,
was 5.4 (2.1) at baseline and decreased to 5.0 (1.5) at the one
year follow up visit (p=0.12).
Effect of storage duration on lipid levels
Overall, storage duration of baseline samples did not inﬂuence
total cholesterol levels. However, the estimated decrease for
HDL cholesterol was 0.15 for each storage year (ﬁg 2).
DISCUSSION
This study shows that patients with early RA with active dis-
ease present with low concentrations of cholesterol and HDL
cholesterol. Although both total and HDL cholesterol levels
appear to be only moderately decreased the total cholesterol/
HDL ratio is at least 5.1 at baseline. This so-called atherogenic
index is an important prognostic marker for future cardiovas-
cular disease; the desirable ratio is four or lower.14 15 A higher
index implies an increased cardiovascular risk, and lowering
this ratio has been shown to decrease this risk—for example,
lowering the ratio from 6.0 to 4.5 halves the ﬁve year rate of
coronary artery disease in women.16 Our longitudinal investi-
gations indicated an improvement of the atherogenic index by
antirheumatic treatment, which might result in a lower
Figure 1 Changes in total cholesterol, HDL cholesterol, and the
atherogenic index (chol/HDL) in the COBRA trial.
Figure 2 HDL cholesterol levels at baseline related to storage
duration.
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(future) cardiovascular risk, provided that the improvement is
maintained over a longer period.
In the COBRA trial the rapidity of response was faster in the
group receiving combined treatment. Owing to the design of
the trial, we are unable to answer the question as to whether
this is the result of better disease suppression, speciﬁc to one
of the components or even their combination. However,we did
ﬁnd a linear relationship between the DAS28 score and the
atherogenic index in both early and established RA.
Regression analyses of the COBRA data showed that changes
in total cholesterol were best predicted by changes in ESR, but
the model for changes in HDL cholesterol also contained dis-
ease activity at baseline and treatment group as additional
factors. These ﬁndings suggest that changes in total choles-
terol are the result of effective RA treatment, but changes in
HDL are more speciﬁc to glucocorticoid (or combination)
treatment.
To our surprise, and not reported before, HDL cholesterol
(but not total cholesterol) levels were strongly inﬂuenced by
storage duration of the samples. Hence, the absolute values of
the atherogenic index in all except the latest (early arthritis
clinic 2001) samples, should be interpreted cautiously, as they
are too low. However, the differences between the trial groups,
and the changes over the year (and their determinants) can
still be studied validly.
Therefore, comparisons between the patients with estab-
lished RA whose disease is active and those in remission and
of both groups with the COBRA group remain valid.
It is well known that physical activity has beneﬁcial effects
on the total cholesterol/HDL cholesterol ratio. In the trans-
verse comparisons of patients with established RA who have
active disease and those in remission such an effect cannot be
excluded. However, the similarity in Health Assessment Ques-
tionnaire scores makes this explanation for the lipid ﬁndings
less likely. In the trial COBRA patients with RA improved
much more rapidly than patients receiving sulfasalazine, and
the former may well have increased their physical activity.
However, it seems unlikely that this would have such major
effects on blood lipids in such a short period of time.
The lipid proﬁle may be also inﬂuenced by weight/body
mass index or drugs such as antimalarial drugs or statins. In
the transverse comparisons there were no signiﬁcant differ-
ences in body weight. In the trial, both groups gained weight,
(about 3 kg in 56 weeks, difference NS), but the COBRA group
gained weight more rapidly in the ﬁrst 28 weeks. Only a very
few patients were receiving antimalarial drugs and/or statins.
Moreover, these drugs were equally distributed between the
several groups. In the COBRA trial such drugs were not used.
Altogether, the combination of cross sectional and longitu-
dinal evidence appears strong. Our ﬁndings indicate an
atherogenic lipid proﬁle in active RA, especially in untreated
patients with early RA, which improves on treatment. The
concomitant changes in body weight suggest a state of rheu-
matoid cachexia at baseline.17 This is supported by a recent
uncontrolled investigation in 42 patients with early RA which
also indicated improvement of the lipid proﬁle in the 27
patients who responded to antirheumatic treatment.18
Thus far published reports are contradictory about the
effect of glucocorticoids in RA, and data of properly designed
studies are lacking. The controlled COBRA data indicate that
glucocorticoid (combination) treatment increases total chol-
esterol and HDL cholesterol more quickly, with a concomitant
faster improvement of the atherogenic index, than sulfa-
salazine alone. Whether or not this favourable inﬂuence on
the cardiovascular risk is ultimately offset by adverse
cardiovascular effects of long term glucocorticoid
administration—for example, hypertension and insulin
resistance,19 remains to be established.
There is an increasing awareness that patients with RA have
an enhanced cardiovascular risk, which appears to be, at least
partly, caused by inﬂammation.1 Our study shows that
inﬂammation (disease activity) has a negative inﬂuence on
the lipid proﬁle and that effective treatment can ameliorate
this.
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